Clinical trial
Efficacy and Safety of Low-dose Chemotherapy Combined With Immuno-targeted Drugs in Newly Diagnosed Adult Patients With Ph-negative B-cell Acute Lymphocytic Leukemia: A Prospective, Single-arm Clinical Study
NCT06387121 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Low-dose Chemotherapy Combined With Immuno-targeted Drugs in Newly Diagnosed Adult Patients With Ph-negative B-cell Acute Lymphocytic Leukemia: A Prospective, Single-arm Clinical Study
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- April 2, 2024
- Completion date
- December 31, 2028
- Enrollment
- 53 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.